Sort   by:  
 Page size 
TranscriptomicsEffect of ruxolitinib treatment on gene expression in triple-negative breast cancer cell lines
HCC1143, HCC70, HCC38, and SUM159PT cells were treated for 4 or 24 hrs with 1uM ruxolitinib. Control cells were treated for 24 hrs with DMSO (0.1%). The purpose was to determine changes in gene expresison patterns following inhibition of JAK1/2 in the cells. Three independent experiments were condu...
ORGANISM(S): Homo sapiens 
2015-12-31 | E-GEOD-70508 | biostudies-arrayexpress
TranscriptomicsRNA-seq of human leukemia cell lines, MHH-CALL-4 and MUTZ-5, treated either with Ruxolitinib, FX1, or their combination.
CRLF2-rearranged acute lymphoblastic leukemia (ALL) is associated with poor clinical outcomes. Although JAK1/2 is activated in this type of ALL, treatment with JAK1/2 inhibitors is insufficient in inhibiting cell growth and inducing apoptosis. BCL6 upregulation upon JAK inhibition may account for th...
ORGANISM(S): Homo sapiens 
2022-07-31 | E-MTAB-10755 | biostudies-arrayexpress
GenomicsToxicicty of ruxolitinib in normal mice
Toxicicty of ruxolitinib in normal mice
PRJNA1005604 | ENA
UnknownSafety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.
Not available
S-EPMC6089176 | biostudies-literature
GenomicsRuxolitinib reduces macrophage pyroptosis in aplastic anaemia
Ruxolitinib reduces macrophage pyroptosis in aplastic anaemia
PRJNA1235629 | ENA
ClinicalAn Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated. This study will also p...
2229234 | ecrin-mdr-crc
GenomicsRNAseq analysis of ruxolitinib treated breast cancers
RNAseq analysis of ruxolitinib treated breast cancers
PRJNA418761 | ENA
ClinicalStudy of Ruxolitinib in Colorectal Cancer Patients
The purpose of this study was to determine if ruxolitinib, in combination with regorafenib, is safe and effective in the treatment of metastatic colorectal cancer.
2165161 | ecrin-mdr-crc
GenomicsDifferential expression and pathway enrichment in neutrophils treated with Ruxolitinib and vehicle
Differential expression and pathway enrichment in neutrophils treated with Ruxolitinib and vehicle
PRJNA794200 | ENA
GenomicsLow dose ruxolitinib plus cyclosporine to treat murine immune-mediated bone marrow failure
Low dose ruxolitinib plus cyclosporine to treat murine immune-mediated bone marrow failure
PRJNA1005605 | ENA
Sort   by:  
 Page size